Corbion (CRBN) CMD 2025 summary

Strategic Achievements and Transformation

• Achieved Advance 2025 goals, including margin expansion from 13% to 16%, 10 consecutive quarters of positive free cash flow, and a 9% sales CAGR with 8% EBITDA CAGR from 2020-2025.

• Transitioned to a high-growth specialty food-ingredients focus, divested low-growth businesses, and invested in a new lactic acid plant in Thailand.

• Turned Algae Omega-3 from loss-making to profitable and scaled the business from EUR 13 million to EUR 160 million.

• Continued investment in innovation, with €90m allocated and over 2,400 patents/applications, supporting over 700 customer projects.

• Strategic review of the PLA portfolio and defocus on non-food lactic acid derivatives to prioritize core food and nutrition segments.

Bright 2030 Strategy and Focus Areas

• BRIGHT 2030 aims to position the company as a leader in natural preservation, nutrition, and biomedical polymers, with a focus on clean-label and sustainable solutions.

• Strategic focus on natural preservation, nutrition, and biomedical polymers, with defocus on non-food lactic acid and a strategic review of the PLA portfolio.

• Targeting 3%-6% annual organic sales growth, 18% adjusted EBITDA margin by 2028, and EUR 270 million cumulative free cash flow (2026-2028).

• Capex of €255 million planned for 2026-2028, with a mid-term leverage target of 1.5x-2.5x net debt to EBITDA.

• Four capital allocation priorities: support organic growth, maintain progressive dividends, pursue bolt-on M&A, and use excess cash for share buybacks or special dividends.

Market Trends and Growth Opportunities

• Strong consumer demand for clean label, natural ingredients, and minimally processed foods is accelerating, driven by health trends, regulatory pressure, and aging populations.

• Addressable markets: $3.5 billion in food preservation, $7 billion in shelf life extension, and $7 billion in Omega-3 and sustainable lipids, all with robust growth rates.

• Expansion into new geographies (Asia-Pacific, Latin America) and adjacencies (culinary, seafood, pet food) through acquisitions and innovation.

• Biomedical Polymers and Nutrition (omega-3 oils) are targeted for double-digit growth, leveraging fermentation technology and strategic partnerships.

• Sustainability embedded in portfolio: 98% renewable raw materials, 99% deforestation-free sourcing, and net-zero emissions target by 2050.